Can we change the signals we measure to better understand disease?

Sangeeta Bhatia joins David Berry to discuss new approaches to cancer detection, synthetic biomarkers and the promise of hepatocytes as liver cell therapies. They also explore lessons from Satellite Bio and the Faculty Founder Initiative’s work helping more women turn academic research into companies.

Watch on YouTube: https://youtu.be/zTWQN4gE4pc
More conversations: https://www.averincapital.com/averin-insights

00:00 Introduction

01:07 Early versus wrong

02:20 Rethinking liquid biopsy

07:56 Synthetic biomarkers

13:48 The future of home screening

15:45 Hepatocytes and liver therapies

21:13 The Faculty Founder Initiative

28:14 Models for building companies

30:30 Academia and entrepreneurship

32:26 Women and the founder ecosystem

35:08 Advice for the next generation

38:14 Closing reflections

How do strategic investors identify promising science and help turn it into a company?

Christian Schubert, Vice President and Global Head of AbbVie Ventures, joins David Berry on Averin Insights to discuss early-stage biotech investing, working with founders, and where AI can make a meaningful difference in drug discovery.

The conversation explores how corporate venture capital is evolving, how investors build conviction in emerging biology, and what it takes to move scientific ideas toward new medicines.

Watch on YouTube
Episode page

Averin Capital backs and builds early-stage companies transforming human health through AI and breakthrough technology.
Explore Averin Capital